VITTORIA BIOTHERAPEUTICS
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
VITTORIA BIOTHERAPEUTICS
Social Links:
Industry:
Bioinformatics Biotechnology Test And Measurement
Founded:
2021-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.vittoriabio.com
Total Employee:
1+
Status:
Active
Total Funding:
25 M USD
Technology used in webpage:
Cloudflare Hosting
Similar Organizations
Allogene Therapeutics
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
BioCentriq
BioCentriq is the cell and gene therapy development and manufacturing center.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Direct Biologics
Direct Biologics is an incubation center that manufactures science-based regenerative biological products.
FibroBiologics
FibroBiologics is a regenerative medicine company developing an innovative solution for chronic disease treatment using fibroblast cells.
Stilla Technologies
Stilla Technologies is a Paris-based european biotechnology company.
Triumvira Immunologics
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Arch Oncology
Arch Oncology is a venture-stage biopharmaceutical company.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
University of Pennsylvania
University of Pennsylvania investment in Venture Round - Vittoria Biotherapeutics
Agent Capital
Agent Capital investment in Venture Round - Vittoria Biotherapeutics
The Leukemia & Lymphoma Society’s Therapy Acceleration Program
The Leukemia & Lymphoma Society’s Therapy Acceleration Program investment in Venture Round - Vittoria Biotherapeutics
NYBC Ventures
NYBC Ventures investment in Venture Round - Vittoria Biotherapeutics
Tellus BioVentures
Tellus BioVentures investment in Venture Round - Vittoria Biotherapeutics
BioAdvance
BioAdvance investment in Venture Round - Vittoria Biotherapeutics
Valley Forge Investment Corporation
Valley Forge Investment Corporation investment in Venture Round - Vittoria Biotherapeutics
Penn Medicine Co-Investment Program
Penn Medicine Co-Investment Program investment in Seed Round - Vittoria Biotherapeutics
SV Health Investors
SV Health Investors investment in Seed Round - Vittoria Biotherapeutics
Tellus BioVentures
Tellus BioVentures investment in Seed Round - Vittoria Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-16 | Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer |
Official Site Inspections
http://www.vittoriabio.com Semrush global rank: 8.5 M Semrush visits lastest month: 523
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vittoria Biotherapeutics"
Homepage - viTToria Biotherapeutics
Nov 25, 2024 REIMAGINING T-CELL ENGINEERING to unlock the promise of immunotherapy A treatment approach with the potential to transform patient outcomes Vittoria Biotherapeutics is a clinical-stage company with a novel …See details»
Vittoria Biotherapeutics - Crunchbase Company Profile …
Vittoria Biotherapeutics is a gene-edited cell therapeutics company. View contacts for Vittoria Biotherapeutics to access new leads and connect with decision …See details»
Vittoria biotherapeutics
CAR T-CELL THERAPY HAS DEMONSTRATED THE POTENTIAL FOR CURATIVE OUTCOMES, BUT LIMITATIONS REMAIN At Vittoria, we are focused on discovering and …See details»
Vittoria Biotherapeutics | Leukemia and Lymphoma Society
Nov 14, 2023 For more information about Vittoria, visit vittoriabio.com. Recent News. ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax …See details»
Vittoria Biotherapeutics, Inc. | LinkedIn
Vittoria Biotherapeutics, Inc. | 1,746 followers on LinkedIn. Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies to address unmet clinical needs. | Vittoria ...See details»
viTToria Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Nov 1, 2024 To learn more, visit vittoriabio.com and follow us on LinkedIn. Investor Contact Vittoria Biotherapeutics Nicholas A. Siciliano, Ph.D. Chief Executive Officer +1 215-600-1380 …See details»
ViTToria Biotherapeutics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for ViTToria Biotherapeutics. Use the PitchBook Platform to explore the full profile.See details»
Vittoria Biotherapeutics - Craft
Vittoria Biotherapeutics has 5 employees at their 1 location and $25 m in total funding,. See insights on Vittoria Biotherapeutics including office locations, competitors, revenue, financials, …See details»
ViTToria Biotherapeutics - Products, Competitors, Financials, …
To learn more, visit vittoriabio.com and follow us on LinkedIn . Investor Contact. Apr 16, 2024. Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer. Apr 16, 2024. …See details»
Vittoria Biotherapeutics, Inc. (viTToria) - VentureRadar
Website: https://vittoriabio.com/ Develops innovative chimeric antigen receptor therapies using advanced cell engineering and gene editing technologies to address ...See details»
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform …
Jul 10, 2023 MaxCyte’s Flow Electroporation® technology and ExPERTâ„¢ platform will support Vittoria’s Senza5â„¢ technology to enhance efficacy and improve clinical utility of T-cell …See details»
Vittoria Biotherapeutics Secures Over $15 Million in
Nov 14, 2023 To learn more, visit vittoriabio.com and follow us on LinkedIn. Investor Contact. Vittoria Biotherapeutics Nicholas A. Siciliano, Ph.D. Chief Executive Officer +1 215-600-1380. …See details»
Vittoria Therapeutics Announces Appointment of Life Sciences …
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary …See details»
ViTToria Biotherapeutics Secures $15M - Penn Center for Innovation
Nov 29, 2023 ViTToria Biotherapeutics, a company co-founded by Marco Ruella, MD, an Assistant Professor of Medicine at Penn Medicine and the scientific director of the lymphoma …See details»
Insider insights: Vittoria CEO Nicholas Siciliano on the future of …
3 days ago In an exclusive interview, viTToria Biotherapeutics' CEO Nicholas Siciliano delves into CAR-T therapy's current limitations, future possibilities, and the innovations needed to …See details»
Vittoria Biotherapeutics Secures Over $15 Million in Private …
Nov 14, 2023 Funds to support advancement of lead candidate, VIPER-101, to the clinicPHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today …See details»
TECHNOLOGY - vittoriabio.com
OUR SENZA5TM PLATFORM TECHNOLOGY IS PRODUCING INNOVATIVE, DIFFERENTIATED, ENABLED AUTOLOGOUS CELL THERAPIES SIGNALING …See details»
Vittoria Biotherapeutics Announces FDA Clearance of IND …
PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug …See details»
Vittoria Biotherapeutics Announces the Presentation of New
Nov 29, 2023 To learn more, visit vittoriabio.com and follow us on LinkedIn. Affiliations with the University of Pennsylvania Dr. Ruella is the scientific founder of, and an equity holder in, …See details»
Vittoria Bio Secures $15 Million to Support Development of Novel …
Nov 14, 2023 Rare Daily Staff. Vittoria Biotherapeutics said it has secured more than $15 million in a private financing round that will be used to advance its lead candidate, VIPER-101, for the …See details»